| |
|
|
|
Xtalks, Online
2024-06-04
Attend an informative webinar discussing the link between digestive health and pro-/post-biotics using data from first human clinical data on patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Increasingly, pre-clinical and clinical research supports the importance of gut health in a wide variety of physiological systems, ranging from digestive health and immune function support to cardiovascular and mental health. With nearly 80 percent of consumers recognizing the link between digestive health and overall well-being, it is not surprising this category is the largest amongst biotic products.
ADM’s most recent clinical study uses the dual probiotic and postbiotic Bifidobacterium longum ES1 in a population of adults with diarrhea-predominant IBS-D. In this webinar, the speaker will walk through the main findings from this study and the science around digestive health and postbiotics.
By attending this webinar, the attendees will gain insights into the following:
Latest clinical trial data from a large multi-centre randomized controlled trial
Explore the use of postbiotics for digestive health
First human clinical data for a dual pro- and post-biotic
Register for this webinar today to explore invaluable insights from a large multi-center randomized controlled trial and first human clinical data for a novel dual pro- and postbiotic for diarrhea-predominant IBS-D.
Keywords: Clinical Trials, Clinical Research, Clinical Data, Marketing, Probiotics, Nutraceuticals, Gut Health, IBS, Gut Microbiome
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Richard Day, VP of Medical Affairs, ADM
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-06-04
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|